Like other business around the world, Starpharma continues to closely monitor the COVID-19 pandemic and its impact.
The health and safety of our people, trial patients and VivaGel® customers is paramount. Starpharma has implemented a broad program of measures to protect the health and safety of our staff and clinical trial patients, and to ensure product supply to customers.
Starpharma has a COVID-19 Safe Plan in place. This includes mitigation actions in specific areas including stringent hygiene, cleaning, physical distancing, record keeping and response preparation in the event of a suspected or confirmed COVID‑19 case. There are work from home arrangements in place (if required) for all staff that can undertake their roles remotely.
Laboratory and in-house GMP manufacturing facilities continue to operate with strict adherence to the requisite COVID-19 Safe Plan.
In Starpharma’s clinical trials, there have been some temporary disruptions to new patient recruitment associated with the impact of COVID-19 on trial sites. Recruitment has resumed in most trial sites, and a number of new sites have been opened.
Starpharma continues to make every effort to minimise any disruption to its supply chain. As experienced by companies around the world, VivaGel® BV partners have had some disruption to their sales and marketing activities, and the COVID-19 lockdowns have delayed some launches and may impact consumer demand.
Starpharma’s management team continues to monitor the situation daily and will update its policies based on current medical advice and Government directives, as required.